Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide
US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been...
NYSE: PFE
Pfizer China Restructures Oncology and Rare Disease Units for Enhanced Focus
Pfizer China (NYSE: PFE) announced on August 11, 2025, an organizational optimization of its Oncology and...
CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer
CureVac N.V. (NASDAQ: CVAC) announced on August 7, 2025, that it has reached an agreement...
Arvinas and Pfizer’s Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer
Arvinas, Inc. (NASDAQ: ARVN) and its partner Pfizer (NYSE: PFE) announced on August 8, 2025,...
Pfizer’s Q2 2025 Revenue Rises 10% Driven by Strong Biopharma Sales
US-based Pfizer Inc. (NYSE: PFE) reported Q2 2025 financial results, revealing a 10% year-on-year (YOY)...
Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod
US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...
3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707
China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...
Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer
Partners Pfizer (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced positive topline results from...
QuantumPharm and Pfizer Expand Collaboration on Advanced Molecular Simulation Platform
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), has announced an expansion of its...
Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections
US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China’s...
EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen
Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...
Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China
US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...
Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area
US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...
Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages
US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China’s...
Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...
Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy
US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...
Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...
Fujian Kerui’s Generic Sirolimus Gel Approved by China’s NMPA
China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer’s (NYSE: PFE)...
Pfizer and Flagship Pioneering Collaborate on AI-Driven Drug Development
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a collaboration agreement with Flagship...
Pfizer Expands Abrysvo RSV Vaccine Indication to Include Ages 18-59 in EU
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has amended the marketing...